CRTX - Cortexyme COR588 for bacterial infection shows safety in phase 1 trial preliminary data

Cortexyme (NASDAQ:CRTX) said its drug COR588 was well-tolerated and safe in a single ascending dose (SAD) portion of a phase 1 trial. The company is developing COR588 to treat diseases related to P. gingivalis (a type of bacteria) infection. In the SAD portion, which enrolled 32 people, of the phase 1 trial, preliminary results suggested that COR588 was well-tolerated across all four cohorts in the dose range from 25 mg to 200 mg with no serious adverse events. No clinically significant findings were seen on other safety measures. “We are encouraged by the initial safety results and look forward to sharing the full data set from the COR588 Phase 1 trial in the second quarter of 2022 once the multiple ascending dosing phase is complete," said Cortexyme's Chief Medical Officer Michael Detke.

For further details see:

Cortexyme COR588 for bacterial infection shows safety in phase 1 trial preliminary data